Dianbao Zuo

机构：Hubei University of Medicine, Huazhong Agricultural University · ORCID：0000-0002-7574-3808

发表论文 12 篇 · 总被引 92 次 · h-index 6

代表论文

• Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects (2024 · Pharmacological Research · 被引 24)
• Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice (2021 · Molecular Cancer Therapeutics · 被引 14)
• Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer (2025 · Frontiers in Immunology · 被引 11)
• A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding (2024 · Biomedicine & Pharmacotherapy · 被引 9)
• Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer (2023 · Journal of Cancer Research and Clinical Oncology · 被引 9)
• Targeting CD16A on NK cells and GPC3 in hepatocellular carcinoma: development and functional validation of a therapeutic bispecific antibody (2025 · Frontiers in Immunology · 被引 6)